News

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...
Investor's Business Daily on MSN4h
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
How Ozempic’s maker lost its grip on the obesity market it created
Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...
Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs
Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
Dow Jones Top Company Headlines at 1 AM ET: Paramount Has Offered $15 Million to Settle CBS Lawsuit. Trump Wants More. | Nvidiaâ s ...
Paramount Has Offered $15 Million to Settle CBS Lawsuit. Trump Wants More. The president's team threatened another lawsuit amid settlement talks. The AI chip maker's shares rose more than 5% after ...
Endocrinology Advisor15h
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.